Atlas Trials

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Clinical trial NCT02879695 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02879695
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent B Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory Mixed Phenotype Acute Leukemia
Start date
2017-10-25
Primary completion
2023-05-22
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.